Saxenda vs Ozempic: Key Differences for Weight Management in the UK

Reading time: 13 minutes
Reading mode:

Saxenda vs Ozempic at a glance

While both Saxenda and Ozempic belong to the same class of GLP-1 receptor agonist medicines, they are distinct products with different regulatory purposes in the UK. The primary distinction lies in their authorised indication: Saxenda is licensed specifically for weight management, whereas Ozempic is licensed for the treatment of type 2 diabetes.

The following table outlines the core differences relevant to a weight-loss query.

| Feature | Saxenda | Ozempic |

| :— | :— | :— |

| Active ingredient | Liraglutide | Semaglutide |

| UK authorised use | Weight management in adults with a BMI of 30 kg/m² or higher, or between 27-30 kg/m² with weight-related conditions. | Blood glucose control in adults with insufficiently controlled type 2 diabetes. Weight loss is not its listed indication. |

| Injection frequency | Once daily | Once weekly |

| Target patient group | Adults seeking clinical support for obesity or overweight, alongside diet and physical activity changes. | Adults managing type 2 diabetes. It is not a like-for-like weight-loss alternative to Saxenda. |

Because their licences differ, the two medicines are not interchangeable. Saxenda represents the standard UK-approved injectable option dedicated to weight management, while Ozempic addresses metabolic control in type 2 diabetes. Although some patients prescribed Ozempic for diabetes may experience weight reduction as a result, it is not authorised for this purpose in isolation. Eligibility and suitability depend on your specific health profile and treatment goals.

Are Saxenda and Ozempic the same medicine?

Despite sharing a medication class, Saxenda and Ozempic are distinct pharmaceutical products rather than interchangeable brands of the same drug. The active ingredients differ fundamentally: Saxenda contains liraglutide, while Ozempic contains semaglutide. Both molecules are glucagon-like peptide-1 (GLP-1) receptor agonists designed to mimic natural hormones that regulate blood sugar and appetite. Their chemical structures result in different durations of action within the body, which directly influences how they must be administered.

The distinction between these two substances is critical for understanding why they are prescribed differently. Sharing a mechanism of action does not equate to identical potency or dosing schedules. Liraglutide has a shorter half-life compared to semaglutide, requiring once-daily injection to maintain consistent levels in the bloodstream. Semaglutide is formulated for slower absorption and elimination, allowing for once-weekly administration. This pharmacological difference ensures that one cannot simply substitute milligram-for-milligram equivalents or switch between the two without specific clinical supervision and adjusted protocols. While they operate through similar biological pathways, they remain separate medicines with unique safety profiles, titration requirements, and regulatory indications.

Test your knowledge with a few quick questions. Choose one answer for each question and see how well you know the topic.

Saxenda vs Ozempic: Key Distinctions

What is the UK-authorised indication for Ozempic?

UK-approved uses and eligibility

In the UK, Saxenda is licensed as a treatment for adult weight management when used alongside a reduced-calorie diet and increased physical activity. Eligibility is defined by body mass index (BMI) thresholds. Adults with a BMI of 30 kg/m² or higher qualify for treatment. Alternatively, adults with a BMI between 27 kg/m² and under 30 kg/m² may also be eligible if they have at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia. The prescription is intended to support those who require clinical intervention to achieve sustainable weight reduction.

Ozempic holds a different regulatory position. Its UK licence authorises it strictly for improving blood glucose control in adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. Weight management is not listed as an indication for Ozempic. The medicine is not a like-for-like alternative to Saxenda for individuals without type 2 diabetes who are seeking treatment primarily for obesity or overweight.

Are you primarily seeking treatment for weight management or blood glucose control?

While healthcare professionals may occasionally consider Ozempic for patients who have both type 2 diabetes and excess weight, this remains distinct from its primary authorised use. It should not be assumed that a prescription for one indication automatically extends to the other. Treatment decisions rely on verifying which licence applies to the individual's specific health needs. Saxenda includes a structured review period; if an adult has not lost at least 5% of their initial body weight after 12 weeks at the maximum maintenance dose, treatment should be discontinued. This ensures that therapy is only continued when it delivers meaningful clinical benefit.

How they work and why dosing frequency differs

Saxenda and Ozempic function as GLP-1 receptor agonists, a class of medicines that mimic the action of the natural hormone glucagon-like peptide-1. By binding to these receptors, both liraglutide (in Saxenda) and semaglutide (in Ozempic) trigger glucose-dependent effects on insulin secretion and glucagon suppression. This helps regulate blood sugar levels. Beyond glycaemic control, these medicines influence appetite and energy intake, which contributes to weight reduction in individuals with excess weight or obesity.

Despite this shared mechanism, the two molecules possess different pharmacokinetic profiles, which directly dictates their dosing frequency. Liraglutide has a shorter duration of action within the body, requiring it to be administered once daily to maintain consistent therapeutic levels. Semaglutide is formulated for slower absorption and elimination from the bloodstream. This extended duration allows semaglutide to remain effective with only a single injection per week.

This difference means that dosing frequency cannot be viewed simply as a matter of convenience; it reflects fundamental chemical distinctions between the two drugs. The once-weekly schedule of Ozempic does not imply a higher total dose compared to Saxenda's daily regimen, nor can the doses be compared milligram for milligram. Each molecule requires its specific administration interval to achieve the intended pharmacological effect safely and effectively.

Doses, injections and treatment review

Saxenda and Ozempic follow different titration schedules that reflect their distinct authorised indications and dosing frequencies. Saxenda is administered as a subcutaneous injection once daily, which can be given at any time of day independently of meals. The standard adult schedule begins at 0.6 mg per day. This starting dose is maintained for one week to help manage initial side effects, after which the dose increases by 0.6 mg increments at intervals of at least one week until reaching the maintenance dose of 3.0 mg daily.

Ozempic is administered as a subcutaneous injection once weekly, with or without meals. The injection can be given in the abdomen, thigh, or upper arm, and while the day of administration can be changed, subsequent injections must remain at least three days apart if the day is switched. The labelled adult schedule starts at 0.25 mg weekly for four weeks. This initial dose serves to introduce the body to the medicine and is not a maintenance dose for glycaemic control. After four weeks, the dose increases to 0.5 mg weekly. Based on tolerability and efficacy, the dose may then be increased at intervals of at least four weeks to 1 mg, and potentially to a maximum recommended dose of 2 mg weekly for further blood glucose management.

Person administering a subcutaneous injection into the thigh using a pre-filled pen

A critical point for readers comparing these options is that the milligram doses cannot be equated directly. The numerical values represent different molecular weights and pharmacological potencies between liraglutide and semaglutide. Ozempic's dosing escalation is designed primarily to achieve specific targets for blood sugar control in type 2 diabetes, whereas Saxenda's daily titration aims to reach a consistent level of appetite suppression for weight management.

For Saxenda specifically, there is a structured treatment review mechanism. If an adult patient has not lost at least 5% of their initial body weight after 12 weeks of treatment at the full maintenance dose of 3.0 mg daily, current UK guidance recommends discontinuing the medicine. This review ensures that therapy is only continued when it is delivering meaningful clinical benefit, preventing unnecessary exposure to a medication that is not meeting individual treatment goals.

Which medicine produces more weight loss?

Direct comparative evidence for weight loss comes from the STEP 8 randomised clinical trial, which investigated these specific molecules in adults with overweight or obesity who did not have diabetes. The study compared semaglutide 2.4 mg administered once weekly against liraglutide 3.0 mg administered once daily. All participants received standard counselling for diet and physical activity changes throughout the trial.

After 68 weeks, the trial reported significant differences in average weight reduction between the two groups. Participants receiving semaglutide 2.4 mg experienced an estimated mean body-weight change of -15.8%, whereas those on liraglutide 3.0 mg lost a mean of -6.4%. This represented a difference of 9.4 percentage points in favour of the higher-dose semaglutide regimen.

Interpret this data within its correct regulatory and clinical context. The STEP 8 trial tested semaglutide 2.4 mg weekly, which is the dose associated with Wegovy, the UK product specifically authorised for weight management. It did not test Ozempic (semaglutide 0.5-2 mg) as a weight-loss treatment. The study does not provide direct evidence that Ozempic produces the same magnitude of weight loss as Saxenda.

The results indicate that when comparing the licensed weight-management doses, semaglutide 2.4 mg was associated with greater average weight reduction than liraglutide 3.0 mg. These figures represent group averages from a clinical trial and cannot be used to forecast individual outcomes. The trial demonstrates how different dosages of distinct molecules perform against each other in a controlled setting, but it does not imply that the standard Ozempic diabetes doses will yield similar results for weight loss.

Side effects, warnings and special considerations

Gastrointestinal adverse reactions are prominent with both Saxenda and Ozempic. Nausea, vomiting, and diarrhoea are common, and in some cases severe enough to cause dehydration. Both UK labels warn that these symptoms can rarely lead to a deterioration of renal function in susceptible individuals. Patients should maintain adequate hydration, particularly during dose escalation or if gastrointestinal symptoms persist.

Severe abdominal pain may indicate acute pancreatitis. Both medicines carry warnings regarding this risk. Persistent, severe abdominal pain that may radiate to the back, with or without vomiting, requires urgent medical assessment. The presence of a known history of pancreatitis is a significant consideration when evaluating suitability for either treatment.

Gallbladder disease is another established risk associated with these therapies. The Saxenda label specifically reports higher rates of cholelithiasis and cholecystitis in weight-management trials compared to placebo. Patients experiencing symptoms such as jaundice, clay-coloured stools, or right upper quadrant pain should seek immediate medical attention.

Specific safety considerations differ between the two active ingredients. Ozempic carries warnings regarding diabetic retinopathy complications, particularly in patients with a history of the condition. There is also epidemiological evidence linking semaglutide exposure to an increased relative risk of non-arteritic anterior ischaemic optic neuropathy (NAION). Patients experiencing sudden partial or complete vision loss should discontinue Ozempic and obtain urgent ophthalmological referral. Saxenda does not carry these specific warnings, though comprehensive eye examinations are often recommended for patients with diabetes regardless of the treatment chosen.

Neither medicine is suitable during pregnancy or breastfeeding. Semaglutide should be stopped at least two months before a planned pregnancy due to its long half-life. Liraglutide should also be discontinued if pregnancy occurs or is planned. These medicines should not be used together or with another GLP-1 receptor agonist, including Wegovy, due to the lack of safety data regarding combined use and the potential for compounded adverse effects.

Individual medical history significantly influences suitability. Pre-existing conditions affecting the pancreas, kidneys, or thyroid gland may require careful evaluation before starting treatment. Patients must discuss their full medical background with a prescriber to weigh these potential risks against the expected benefits of therapy.

Where Wegovy fits into the comparison

Wegovy is a UK-authorised medicinal product that contains semaglutide, the same active ingredient found in Ozempic. Identical active ingredients do not make these brands interchangeable. They are separately authorised products with distinct intended uses and regulated dose-escalation frameworks.

The primary distinction lies in their regulatory licence. Wegovy is specifically authorised for chronic weight management in adults with obesity or overweight accompanied by weight-related conditions. Ozempic is licensed solely for improving blood glucose control in adults with insufficiently controlled type 2 diabetes. These differing licences dictate specific dosing limits and clinical pathways that prevent patients from assuming the two products are clinically equivalent despite their shared molecular structure.

Understanding this distinction clarifies the context of weight-loss trials such as STEP 8. That trial compared liraglutide (the active ingredient in Saxenda) against semaglutide 2.4 mg weekly. It did not test Ozempic, because Ozempic's maximum labelled dose is 2 mg weekly. The semaglutide regimen used in the study matches the dosing associated with Wegovy. When discussing efficacy evidence for weight reduction, Saxenda versus Wegovy represents a fairer comparison than Saxenda versus Ozempic.

This does not diminish the reality that patients prescribed Ozempic for diabetes may experience weight loss as a beneficial secondary effect. Clinicians cannot prescribe Ozempic primarily for obesity treatment within its current UK licence. Patients without diabetes seeking medical weight management generally require Wegovy or Saxenda rather than Ozempic, depending on their specific health profile and eligibility criteria. Recognising the separate identities of these brands prevents confusion regarding expected outcomes, dosing limits, and appropriate prescribing pathways.

How to discuss the options with a prescriber

Choosing between Saxenda and Ozempic requires a structured clinical assessment rather than a simple preference for injection frequency or brand recognition. Because these medicines serve different primary regulatory purposes in the UK, determining suitability depends on your specific diagnosis and health history.

Prepare to discuss the following points with your clinician:

  • Primary Diagnosis: Be clear about whether you have type 2 diabetes or are seeking treatment for overweight/obesity without diabetes. This determines which licence applies. If you lack type 2 diabetes, Ozempic is not the appropriate authorised choice for weight loss alone; Saxenda (or Wegovy) would be the relevant pathways to evaluate based on your BMI and comorbidities.
  • Treatment Goals: Discuss whether immediate blood glucose control is urgent or if the primary focus is sustainable weight reduction. Ozempic targets glycaemic control, whereas Saxenda is structured around achieving significant weight loss alongside lifestyle changes.
  • Injection Frequency Preference: Consider your daily routine. Saxenda requires a daily injection, which some patients find easier to remember but burdensome long-term. Ozempic requires a weekly injection, offering less frequent administration but a different titration schedule. Neither option is universally superior; adherence depends on personal habit and tolerability.
  • Previous Response and Side Effects: Share any history with other weight-loss or diabetes treatments. Mention specific side effects you have experienced previously, particularly gastrointestinal issues, pancreatitis, or gallbladder disease. Both medicines carry overlapping risks for nausea and vomiting, but Saxenda carries a higher reported risk of gallbladder problems, while Ozempic carries specific warnings regarding diabetic retinopathy and vision complications.
  • Pregnancy Plans: Inform your prescriber if you are pregnant, breastfeeding, or planning a pregnancy. Both medicines are contraindicated during these periods. Semaglutide (Ozempic) must be stopped at least two months before a planned pregnancy due to its long half-life, whereas liraglutide (Saxenda) should be discontinued immediately if pregnancy is detected or planned.
  • Concurrent Medications: Provide a full list of other medicines and supplements. Avoid combining either medicine with another GLP-1 receptor agonist, such as Wegovy, due to safety concerns.

Do not rely solely on trial averages or the convenience of weekly injections when making your decision. A prescriber must weigh your BMI, comorbidities, risk profile, and adherence capacity to determine if Saxenda's daily weight-management focus or Ozempic's weekly glycaemic control is medically appropriate for you.

Would you prefer a daily or weekly injection?
Semaglutide for managing overweight and obesity

Source organization: National Institute for Health and Care Excellence

Liraglutide for managing overweight and obesity

Source organization: National Institute for Health and Care Excellence

Questions & comments

Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.